12:00 AM
 | 
Aug 03, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Saphris asenapine: Preliminary Phase III data

Preliminary data from 146 evaluable patients in a 6-month, active-controlled, Phase III extension trial showed that Saphris asenapine met the primary endpoint of significantly reducing negative symptoms as measured by decrease from baseline in the NSA-16 total score at 1 year vs. Zyprexa olanzapine (15.8 vs. 11 points, p=0.015). The Phase III trial, which enrolled 468 patients, missed the same primary endpoint at 6 months. The extension enrolled 195 patients who maintained the...

Read the full 351 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >